MNCs Eye Nigeria As Hub Of Africa Making Up For Slow Growth Elsewhere
This article was originally published in PharmAsia News
Several multinational drug makers such as GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer and Sanofi are looking to Africa, Nigeria in particular, for markets to make up for reduced growth in developed countries.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.